Cargando…

Adherence to routine use of pharmacological prophylaxis of heterotopic ossification after total hip arthroplasty: results from an Italian multicenter, prospective, observational survey

BACKGROUND: In spite of the proven efficacy of pharmacological prophylaxis of heterotopic ossification following total hip arthroplasty, its routine use is still debated, and no data are available regarding the adherence to its administration in clinical practice. MATERIALS AND METHODS: In this pros...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbato, Michele, D’Angelo, Ezio, Di Loreto, Giuseppina, Menna, Angelo, Di Francesco, Alexander, Salini, Vincenzo, Zoppi, Umberto, Cavasinni, Lino, La Floresta, Pancrazio, Romanò, Carlo Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349017/
https://www.ncbi.nlm.nih.gov/pubmed/22358779
http://dx.doi.org/10.1007/s10195-012-0180-4
_version_ 1782232450151219200
author Barbato, Michele
D’Angelo, Ezio
Di Loreto, Giuseppina
Menna, Angelo
Di Francesco, Alexander
Salini, Vincenzo
Zoppi, Umberto
Cavasinni, Lino
La Floresta, Pancrazio
Romanò, Carlo Luca
author_facet Barbato, Michele
D’Angelo, Ezio
Di Loreto, Giuseppina
Menna, Angelo
Di Francesco, Alexander
Salini, Vincenzo
Zoppi, Umberto
Cavasinni, Lino
La Floresta, Pancrazio
Romanò, Carlo Luca
author_sort Barbato, Michele
collection PubMed
description BACKGROUND: In spite of the proven efficacy of pharmacological prophylaxis of heterotopic ossification following total hip arthroplasty, its routine use is still debated, and no data are available regarding the adherence to its administration in clinical practice. MATERIALS AND METHODS: In this prospective, observational, multicenter study, 480 consecutive patients operated on for primary total hip arthroplasty during the year 2009 were followed radiographically for 12 months after surgery in order to assess the incidence of periprosthetic heterotopic ossification. Surgeons were free to choose whether to administer pharmacological prophylaxis, and were asked to keep a record of the duration of the prophylaxis (if used) or the reasons for not using it. To facilitate the statistical analysis, all of the participating centers agreed to use only one drug (celecoxib) that had already proven to be effective. RESULTS: 368 patients were administered celecoxib and 112 patients did not receive any prophylaxis. Reported reasons for not administering celecoxib prophylaxis were the surgeon’s opinion that prophylaxis was not needed on a routine basis (84/112 patients, 75%), previous history of gastrointestinal bleeding (17.8%), and concomitant cardiorenal pathologies (7.1%). The overall incidence of heterotopic ossification in the celecoxib-treated patients was 23% (no cases of Brooker grade 3 or 4 ossifications), compared to 55% in the untreated patients (Brooker grade 3 and 4: 8.9%). Multivariate analysis showed that celecoxib prophylaxis was the single most important variable when predicting the occurrence of heterotopic ossification. CONCLUSIONS: This study confirms the efficacy and tolerability of celecoxib for the prophylaxis of heterotopic ossification after total hip arthroplasty, and shows how the surgeon’s belief that routine prevention is not required still plays an important role in the determination of this complication, together with the fear of possible unwanted side effects.
format Online
Article
Text
id pubmed-3349017
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-33490172012-05-30 Adherence to routine use of pharmacological prophylaxis of heterotopic ossification after total hip arthroplasty: results from an Italian multicenter, prospective, observational survey Barbato, Michele D’Angelo, Ezio Di Loreto, Giuseppina Menna, Angelo Di Francesco, Alexander Salini, Vincenzo Zoppi, Umberto Cavasinni, Lino La Floresta, Pancrazio Romanò, Carlo Luca J Orthop Traumatol Original Article BACKGROUND: In spite of the proven efficacy of pharmacological prophylaxis of heterotopic ossification following total hip arthroplasty, its routine use is still debated, and no data are available regarding the adherence to its administration in clinical practice. MATERIALS AND METHODS: In this prospective, observational, multicenter study, 480 consecutive patients operated on for primary total hip arthroplasty during the year 2009 were followed radiographically for 12 months after surgery in order to assess the incidence of periprosthetic heterotopic ossification. Surgeons were free to choose whether to administer pharmacological prophylaxis, and were asked to keep a record of the duration of the prophylaxis (if used) or the reasons for not using it. To facilitate the statistical analysis, all of the participating centers agreed to use only one drug (celecoxib) that had already proven to be effective. RESULTS: 368 patients were administered celecoxib and 112 patients did not receive any prophylaxis. Reported reasons for not administering celecoxib prophylaxis were the surgeon’s opinion that prophylaxis was not needed on a routine basis (84/112 patients, 75%), previous history of gastrointestinal bleeding (17.8%), and concomitant cardiorenal pathologies (7.1%). The overall incidence of heterotopic ossification in the celecoxib-treated patients was 23% (no cases of Brooker grade 3 or 4 ossifications), compared to 55% in the untreated patients (Brooker grade 3 and 4: 8.9%). Multivariate analysis showed that celecoxib prophylaxis was the single most important variable when predicting the occurrence of heterotopic ossification. CONCLUSIONS: This study confirms the efficacy and tolerability of celecoxib for the prophylaxis of heterotopic ossification after total hip arthroplasty, and shows how the surgeon’s belief that routine prevention is not required still plays an important role in the determination of this complication, together with the fear of possible unwanted side effects. Springer International Publishing 2012-02-23 2012-06 /pmc/articles/PMC3349017/ /pubmed/22358779 http://dx.doi.org/10.1007/s10195-012-0180-4 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Barbato, Michele
D’Angelo, Ezio
Di Loreto, Giuseppina
Menna, Angelo
Di Francesco, Alexander
Salini, Vincenzo
Zoppi, Umberto
Cavasinni, Lino
La Floresta, Pancrazio
Romanò, Carlo Luca
Adherence to routine use of pharmacological prophylaxis of heterotopic ossification after total hip arthroplasty: results from an Italian multicenter, prospective, observational survey
title Adherence to routine use of pharmacological prophylaxis of heterotopic ossification after total hip arthroplasty: results from an Italian multicenter, prospective, observational survey
title_full Adherence to routine use of pharmacological prophylaxis of heterotopic ossification after total hip arthroplasty: results from an Italian multicenter, prospective, observational survey
title_fullStr Adherence to routine use of pharmacological prophylaxis of heterotopic ossification after total hip arthroplasty: results from an Italian multicenter, prospective, observational survey
title_full_unstemmed Adherence to routine use of pharmacological prophylaxis of heterotopic ossification after total hip arthroplasty: results from an Italian multicenter, prospective, observational survey
title_short Adherence to routine use of pharmacological prophylaxis of heterotopic ossification after total hip arthroplasty: results from an Italian multicenter, prospective, observational survey
title_sort adherence to routine use of pharmacological prophylaxis of heterotopic ossification after total hip arthroplasty: results from an italian multicenter, prospective, observational survey
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349017/
https://www.ncbi.nlm.nih.gov/pubmed/22358779
http://dx.doi.org/10.1007/s10195-012-0180-4
work_keys_str_mv AT barbatomichele adherencetoroutineuseofpharmacologicalprophylaxisofheterotopicossificationaftertotalhiparthroplastyresultsfromanitalianmulticenterprospectiveobservationalsurvey
AT dangeloezio adherencetoroutineuseofpharmacologicalprophylaxisofheterotopicossificationaftertotalhiparthroplastyresultsfromanitalianmulticenterprospectiveobservationalsurvey
AT diloretogiuseppina adherencetoroutineuseofpharmacologicalprophylaxisofheterotopicossificationaftertotalhiparthroplastyresultsfromanitalianmulticenterprospectiveobservationalsurvey
AT mennaangelo adherencetoroutineuseofpharmacologicalprophylaxisofheterotopicossificationaftertotalhiparthroplastyresultsfromanitalianmulticenterprospectiveobservationalsurvey
AT difrancescoalexander adherencetoroutineuseofpharmacologicalprophylaxisofheterotopicossificationaftertotalhiparthroplastyresultsfromanitalianmulticenterprospectiveobservationalsurvey
AT salinivincenzo adherencetoroutineuseofpharmacologicalprophylaxisofheterotopicossificationaftertotalhiparthroplastyresultsfromanitalianmulticenterprospectiveobservationalsurvey
AT zoppiumberto adherencetoroutineuseofpharmacologicalprophylaxisofheterotopicossificationaftertotalhiparthroplastyresultsfromanitalianmulticenterprospectiveobservationalsurvey
AT cavasinnilino adherencetoroutineuseofpharmacologicalprophylaxisofheterotopicossificationaftertotalhiparthroplastyresultsfromanitalianmulticenterprospectiveobservationalsurvey
AT laflorestapancrazio adherencetoroutineuseofpharmacologicalprophylaxisofheterotopicossificationaftertotalhiparthroplastyresultsfromanitalianmulticenterprospectiveobservationalsurvey
AT romanocarloluca adherencetoroutineuseofpharmacologicalprophylaxisofheterotopicossificationaftertotalhiparthroplastyresultsfromanitalianmulticenterprospectiveobservationalsurvey